CD247 Antibody

What is the optimal protocol for detecting CD247 in peripheral blood lymphocytes?

For effective detection of CD247 in peripheral blood lymphocytes, a multi-step protocol is recommended. Begin with surface staining using membrane-labeled antibodies against CD45, CD3, CD4, and CD8, incubating with patient blood samples at 4°C for 30 minutes in dark conditions. After incubation with hemolysin for 8 minutes, centrifuge at 1200 rpm for 5 minutes and discard the supernatant. Add diluted fixation solution (prepared at 1:3 ratio) and incubate for 8 minutes at 4°C, followed by centrifugation and removal of supernatant. For intracellular CD247 staining, add permeabilization buffer (prepared at 1:9 ratio with distilled water), resuspend cells, and incubate at 4°C for 30 minutes protected from light. This approach enables comprehensive phenotyping of T-cell populations while accurately measuring CD247 expression levels .

How should CD247 antibody be prepared and stored for optimal performance?

CD247 antibodies should be prepared through affinity chromatography on Protein G from ascites to achieve high purity and specificity. The recommended formulation is purified IgG in liquid form, buffered in phosphate buffered saline with 0.09% sodium azide (NaN₃) as a preservative. The optimal concentration for storage is approximately 0.5 mg/ml. When stored properly, these antibodies maintain their activity for up to 12 months from the date of preparation. For applications requiring longer storage, aliquoting the antibody to minimize freeze-thaw cycles is advisable. Always maintain cold chain integrity during handling and storage to prevent degradation of the antibody's binding capacity .

How can researchers effectively evaluate CD247 expression levels in immunohistochemistry?

For quantitative assessment of CD247 expression in immunohistochemistry, the H-score method provides a standardized approach. This method calculates a weighted score based on staining intensity: H-score = (% unstained cells × 0) + (% weakly stained cells × 1) + (% moderately stained cells × 2) + (% strongly stained cells × 3). The resulting scores range from 0 (100% negative staining) to 300 (100% strong staining). For CD247 evaluation specifically, formalin-fixed, paraffin-embedded sections (4-μm thick) should be prepared with appropriate antigen retrieval using 2% EDTA-citrate solution at 125°C for 5 minutes in a pressure cooker. Independent assessment by multiple pathologists is recommended to ensure scoring reliability, with the averaged scores used for statistical analysis .

How can CD247 expression serve as a biomarker for disease severity and prognosis in idiopathic pulmonary fibrosis (IPF)?

CD247 expression has significant potential as a biomarker for IPF severity and prognosis due to its correlation with disease parameters. Multiple datasets demonstrate that CD247 is significantly downregulated in IPF patients compared to controls in both blood and lung tissue samples. Importantly, CD247 expression shows a strong positive association with diffusing capacity for carbon monoxide (DLCO) predicted percentage, a key measure of lung function in IPF. Low CD247 expression has been identified as a risk factor for disease progression, with significant associations to shorter treatment-free survival time. ROC curve analysis reveals good predictive capability, with AUC values of 0.736 at 1 year and 0.741 at 2 years for composite endpoint prediction, and even higher values (0.889, 0.787, and 0.702 at 1, 2, and 3 years respectively) for non-treatment-free survival in some datasets. These findings suggest that monitoring CD247 expression in peripheral blood could provide valuable prognostic information to guide clinical decision-making in IPF management .

What is the relationship between CD247 expression and T-cell function in disease contexts?

CD247 expression closely reflects T-cell functional status in various disease contexts, serving as a critical indicator of immune activity. In conditions such as ovarian cancer, decreased CD247 expression in peripheral blood lymphocytes correlates with altered T-cell functionality. Similarly, in IPF, CD247 downregulation is associated with impaired T-cell responses. This relationship stems from CD247's fundamental role in the T-cell receptor complex, where it mediates signal transduction following antigen recognition. Protein-protein interaction network analysis reveals that CD247 interacts with key signaling molecules including CD3E, ZAP70, LCK, FYN, JAK3, and PTPN6, which collectively regulate T-cell activation, proliferation, and effector functions. Gene Ontology and KEGG pathway analyses further confirm that CD247 and its interacting partners are enriched in immune response pathways, particularly T-cell-related biological processes. Additionally, five genes associated with CD247 (CD247, CD3E, ZAP70, LCK, PTPN6) are involved in the PD-L1 expression and PD-1 checkpoint pathway in cancer, suggesting a potential role in immune checkpoint regulation .

How does CD247 expression change during the progression of fibrotic lung disease in experimental models?

CD247 expression in T cells follows a distinct temporal pattern during the progression of lung fibrosis in experimental models. Single-cell RNA-sequencing data from bleomycin-induced pulmonary fibrosis in mice reveals that Cd247 expression in T cells initially increases during the acute inflammatory phase following injury, then progressively decreases as fibrosis develops. This dynamic expression pattern suggests a transition in T-cell functionality during disease progression. The initial upregulation may reflect active T-cell recruitment and activation in response to tissue injury, while the subsequent downregulation could indicate T-cell exhaustion or dysfunction as fibrosis becomes established. This temporal pattern is consistent with findings from the LungMAP database, which confirms that CD247 is predominantly expressed by T cells and NK cells in both human and mouse lungs. These observations provide important insights into the immunological mechanisms underlying fibrotic disease progression and suggest potential windows for therapeutic intervention targeting T-cell function .

What methodological approaches can resolve contradictory CD247 expression data between different sample types?

Resolving contradictory CD247 expression data between different sample types requires integrated methodological approaches that account for tissue-specific factors and experimental variables. When analyzing discrepancies between blood, lung tissue, and bronchoalveolar lavage fluid (BALF) samples, consider the following strategies:

• Standardize sample collection and processing protocols to minimize technical variability

• Implement appropriate normalization methods to account for differences in cell composition between sample types

• Utilize multiple detection methods (flow cytometry, immunohistochemistry, and gene expression analysis) to validate findings

• Conduct paired analyses of matched samples from the same subjects when possible

• Stratify analyses by disease stage, as CD247 expression dynamics may vary throughout disease progression

What validation criteria should be applied when selecting CD247 antibodies for specific applications?

When selecting CD247 antibodies for research applications, implement a comprehensive validation strategy to ensure reliable results. For Western blotting applications, verify that the antibody detects the expected 18 kDa band in appropriate positive control lysates (such as Jurkat cells) and confirm specificity through negative controls. For flow cytometry and immunohistochemistry, validation should include positive control tissues with known CD247 expression and appropriate isotype controls to assess non-specific binding. Additionally, antibodies should be validated for their intended application as performance can vary significantly between techniques. For instance, antibodies optimized for Western blotting may not perform well in immunoprecipitation or immunohistochemistry. The PrecisionAb designation indicates antibodies that have undergone rigorous validation through standardized protocols, providing an additional level of quality assurance. When selecting between different CD247 antibody clones, consider factors such as the specific epitope recognized, species reactivity, and performance data in your application of interest .

How can researchers effectively isolate and prepare tissue samples for optimal CD247 detection?

Effective tissue processing for CD247 detection requires careful attention to preservation of protein structure and antigenicity. For fresh tissue samples, such as from ovarian cancer or adjacent tissues, begin by rinsing with 1% FBS in Hanks solution, followed by mechanical dissociation with scissors. Enzymatic digestion for 30 minutes at 37°C helps release cells while preserving surface markers. After thorough grinding and filtration, centrifuge at 1500 rpm for 5 minutes and discard the supernatant. For stimulation experiments, resuspend cells with PMA and ionomycin, incubating for 1 hour at 37°C before staining.

For fixed tissue samples, formalin-fixed paraffin-embedded (FFPE) sections should be prepared at 4-μm thickness. Optimal deparaffinization involves immersion in dimethylbenzene three times for 15 minutes each, followed by hydration in decreasing ethanol concentrations (100%, 95%, and 75%) for 5 minutes each. Critical for CD247 detection is effective antigen retrieval, which can be achieved using 2% EDTA-citrate solution at 125°C for 5 minutes in a pressure cooker. This high-temperature retrieval method is essential for exposing the CD247 epitopes that may be masked during fixation. These detailed processing steps ensure optimal preservation of both tissue architecture and antigenicity for accurate CD247 detection .

How can CD247 expression analysis contribute to understanding immune dysfunction in cancer?

CD247 expression analysis provides crucial insights into immune dysfunction in cancer through multiple mechanisms. Studies in ovarian cancer demonstrate that CD247 expression is significantly decreased in peripheral blood lymphocytes from cancer patients compared to those with benign ovarian cysts. This reduction reflects T-cell dysfunction, which may contribute to impaired anti-tumor immunity and disease progression. Quantitative assessment of CD247 expression through methods such as flow cytometry and immunohistochemistry allows researchers to correlate expression levels with clinical parameters, providing potential prognostic information.

The mechanistic significance of CD247 downregulation lies in its role within the T-cell receptor complex. As a critical signaling component, reduced CD247 expression impairs TCR signal transduction, potentially leading to suboptimal T-cell activation and effector functions. This dysfunction may create an immunosuppressive microenvironment that facilitates tumor escape from immune surveillance. Furthermore, the association between CD247 and genes involved in the PD-1/PD-L1 checkpoint pathway suggests potential interactions with established immunotherapy targets. By characterizing these relationships, researchers can develop more comprehensive models of tumor-immune interactions and identify potential therapeutic vulnerabilities or biomarkers for response to immunotherapy .

What are the implications of CD247 as a potential biomarker for monitoring treatment response in fibrotic diseases?

CD247 shows considerable promise as a biomarker for monitoring treatment response in fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). Longitudinal studies demonstrate that CD247 expression levels maintain significant prognostic value at multiple time points during disease course and treatment. Even after follow-up periods of 1, 3, 6, and 12 months, low CD247 expression remains a risk factor for disease progression, suggesting sustained relevance throughout the treatment journey.

The practical implementation of CD247 as a treatment response biomarker involves several key considerations:

This persistent association between CD247 expression and clinical outcomes suggests that serial monitoring could provide valuable information about treatment efficacy. Additionally, the accessibility of CD247 measurement in peripheral blood makes it particularly attractive for longitudinal monitoring, offering a less invasive alternative to repeated lung biopsies. As personalized medicine approaches evolve for fibrotic diseases, CD247 monitoring could potentially guide treatment selection, timing of intervention, or treatment modification based on immunological response patterns .